Serum Fetuin Level in Polycystic Ovary Syndrome | NCT03819998

Studies
Serum Fetuin Level in Polycystic Ovary Syndrome

NCT03819998

Sponsor

Aljazeera Hospital

Status

Unknown status

Last Update Posted

Aug 6, 2019Actual

Enrollment

50Estimated

Phase

Not provided

Conditions

Polycystic Ovary

Interventions

measurement of Fetuin-A level in serum

Countries

Egypt

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Aug 2019

Overall Recruitment Status or Expanded Access Status

Unknown status

Last Known Status

Recruiting

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Jan 30, 2019Actual

Primary Completion Date

Feb 1, 2020Estimated

Completion Date

Feb 5, 2020Estimated

First Submitted Date

Jan 25, 2019

First Submission Date that Met QC Criteria

Jan 25, 2019

First Posted Date

Jan 29, 2019Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Aug 4, 2019

Last Update Posted Date

Aug 6, 2019Actual

Name	Class
Cairo University	OTHER
National Research Centre, Egypt	OTHER

Oversight Module

Has Data Monitoring Committee (DMC)

Yes

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

polycystic ovary syndrome is a common gynecological problem

Detailed Description

Understanding the pathophysiology and the cause is of much importance for proper management of this problem

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

50Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
PCOS group		women who have PCOS	Diagnostic Test: measurement of Fetuin-A level in serum
control group		women who donnot have PCOS	Diagnostic Test: measurement of Fetuin-A level in serum

Interventions

Name	Type	Description	Arm Group Labels	Other Names
measurement of Fetuin-A level in serum	Diagnostic Test	Fetuin A level will be measured in blood of the PCOS women	PCOS group control group

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
The number of women who will have high level of fetuin A and has PCOS	Evaluation of women who have PCOS in relation to fetuin A level	within a week

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

women who have PCOS in group 1 and who donnot have PCOS in group 2 with age between 20 -42 years

Exclusion Criteria:

women above 42 years old

Accepts Healthy Volunteers

Yes

Sex

Female

Sex/Gender Based

Yes

Sex/Gender Description

Women with polycystic ovary syndrome

Minimum Age

18 Years

Maximum Age

42 Years

Standard Ages

Adult

Study Population

women who have PCOS and have symptoms of hyperandrogenism and irregular cycles

Sampling Method

Probability Sample

Contacts/Locations Module

Central Contacts

Name	Role	Phone	Extension	Email
Mahmoud Alalfy, PhD	Contact	01002611058		mahmoudalalfy@ymail.com

Overall Officials

Not provided

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Algazeerah and Kasralainy hospital	Recruiting	Giza			Egypt

Condition Browse Module

MeSH Terms

ID	Term
D011085	Polycystic Ovary Syndrome

Ancestor Terms

ID	Term
D010048	Ovarian Cysts
D003560	Cysts
D009369	Neoplasms
D010049	Ovarian Diseases
D000291

Browse Leaves

Not provided

Browse Branches

Not provided